Please assess the completion status of the following clinical trial:

Trial Title: An Open Label, Proof of Concept Study to Evaluate the Effects of Dalfampridine Withdrawal on Gait and Balance Parameters in Subjects With Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of multiple sclerosis~* Receiving Ampyra® consistently for at least 2 weeks prior to the screening visit~* No history of seizures except simple febrile seizures~Exclusion Criteria:~* Sexually active woman of childbearing potential who is not surgically sterile, \<two years post-menopause or is not using effective birth control methods~* Subject who is pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- dalfampridine-ER 10mg (Type: None): Subjects with MS taking dalfampridine-ER 10mg and considered to be responders

Based on this trial design, predict the completion outcome and termination type (if applicable).